Lauren Sharkey is a litigation and trial associate in the Chicago office of Latham & Watkins. Ms. Sharkey represents pharmaceutical and technology companies in intellectual property disputes including patent litigation and trade secret claims.
She has experience at all stages of litigation, in both federal and state courts: developing case strategies, taking fact and expert witness depositions, examining witnesses at trial, directing various aspects of fact and expert discovery, drafting dispositive motions, and preparing witnesses for depositions.
Prior to joining Latham, Ms. Sharkey served as a law clerk to Judge Nora Barry Fischer of the United States District Court for the Western District of Pennsylvania. Before clerking, Ms. Sharkey worked in-house at IBM. During law school, Ms. Sharkey interned for the US Marshals Services and in the chambers of Judge Thomas M. Hardiman on the United States Court of Appeals for the Third Circuit. She also served as an editor for the Journal of Law, Ethics, and Public Policy.
Ms. Sharkey is the First Chair of the Junior Board of Chicago Volunteer Legal Services (CVLS) and is on the Board of Directors of the Chicago Chapter of the Federal Bar Association and serves as a Co-Chair of its Younger Lawyers Division.
Ms. Sharkey’s experience includes representing:
- AbbVie in multiple worldwide litigations involving top-selling drugs for the treatment of Hepatitis C
- Roxane Laboratories, Inc. as defendant in a Hatch-Waxman patent litigation relating to generic NUCYNTA® (tapentadol hydrochloride) analgesic drug products
- Roxane Laboratories, Inc. for declaratory judgment plaintiff/defendant in two Hatch-Waxman cases involving Roxane’s ANDA for generic ritonavir product (bioequivalent to NORVIR®)
- Par Pharmaceutical as defendant in a Hatch-Waxman case involving Par’s ANDA for generic lubiprostone product (bioequivalent to AMITIZA®)
- Branded pharmaceutical company in Hatch-Waxman litigation, including discovery, pretrial, claim construction, and settlements
- Pro bono, individuals seeking asylum in the United States and the resentencing of a juvenile given life without parole
- In Sucampo et al. v. Par Pharmaceutical et al. (D. Del.) – the defendant in a Hatch-Waxman case involving Par’s ANDA for generic lubiprostone product (bioequivalent to AMITIZA®)